|
[1] Laflamme MA, Murry CE. Heart regeneration. Nature 2011;473:326–335.
[2] Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol 2005;23:845–856.
[3] Watch, Learn and Live: Interactive Cardiovascular Library. American Heart Association. Retrieved Dec 10, 2012, from http://watchlearnlive.heart.org/CVML_Player.php?moduleSelect=hrtatk.
[4] Reichle FA. Criteria for evaluation of new arterial prostheses by comparing vein with dacron femoropopliteal bypasses. Surg Gynecol Obstet 1978;146:714–20.
[5] Matsumoto H, Fuse K, Yamamoto M, Hasegawa T, Saigusa M, Uei I. Studies on the porous polytetrafluoroethylene as the vascular prosthesis. Jinko Zoki 1972;1:44-47.
[6] Araújo JD, Braile DM, Azenha Filho JO, Barros ET, Marconi A. The use of bovine pericardium as an arterial graft. A 5-year follow-up. J Cardiovasc Surg (Torino) 1987;28:434–9.
[7] Ozawa T, Mickle DA, Weisel RD, Koyama N, Wong H, Ozawa S, Li RK. Histologic changes of nonbiodegradable and biodegradable biomaterials used to repair right ventricular heart defects in rats. J Thorac Cardiovasc Surg 2002;124:1157–64.
[8] Dor V, Sabatier M, Di Donato M, Montiglio F, Toso A, Maioli M. Efficacy of endoventricular patch plasty in large postinfarction akinetic scar and severe left ventricular dysfunction: comparison with a series of large dyskinetic scars. J Thorac Cardiovasc Surg 1998;116:50–9.
[9] Langer R, Vacanti JP. Tissue engineering. Science. 1993;260:920–6.
[10] Vacanti JP, Vacanti CA. The challenge of tissue engineering. In: Lanza RP, Langer R, Chick, WL, editors. Principles of Tissue Engineering. Austin, TX: Academic Press, 1997, pp. 1–6.
[11] Tabata Y. Necessity of drug delivery systems to tissue engineering. In: Park KD, Kwon IC, Yui N, Jeong SY, Park K, editors. Biomaterials and drug delivery toward new mellenium. Korea: Han Rim Won Publishing Co., 2000, pp. 531–44.
[12] Rane AA, Christman KL. Biomaterials for the treatment of myocardial infarction a 5-year update. J Am Coll Cardiol 2011;58:2615–29.
[13] Hay ED. Cell Biology of Extracellular Matrix, 2nd ed. New York: Plenum Press, 1991, pp. 45–71.
[14] Chang Y, Tsai CC, Liang HC, Sung HW. In vivo evaluation of cellular and acellular bovine pericardia fixed with a naturally occurring crosslinking agent (genipin). Biomaterials 2002;23:2447–57.
[15] Chang Y, Chen S-C, Wei H-J, Wu T-J, Liang H-C, Lai P-H, Yang H-H, Sung H-W. Tissue regeneration observed in a porous acellular bovine pericardium used to repair a myocardial defect in the right ventricle of a rat model. J Thorac Cardiovasc Surg 2005;130:705–11.
[16] Wei H-J, Chen S-C, Chang Y, Hwang S-M, Lin W-W, Lai P-H, Chiang HK, Hsu L-F, Yang H-H, Sung H-W. Porous acellular bovine pericardia seeded with mesenchymal stem cells as a patch to repair a myocardial defect in a syngeneic rat model. Biomaterials 2006;27:5409–19.
[17] Chen CH, Wei HJ, Lin WW, Chiu I, Hwang SM, Wang CC, Lee WY, Chang Y, Sung HW. Porous tissue grafts sandwiched with multilayered mesenchymal stromal cell sheets induce tissue regeneration for cardiac repair. Cardiovasc Res 2008;80:88–95.
[18] Huang C-C, Liao C-K, Yang M-J, Chen C-H, Hwang S-M, Hung Y-W, Chang Y, Sung H-W. A Strategy for Fabrication of a Three-Dimensional Tissue Construct Containing Uniformly Distributed Embryoid Body-derived Cells as a Cardiac Patch. Biomaterials 2010;31:6218–27.
[19] Okano T, Yamada N, Okuhara M, Sakai H, Sakurai Y. Mechanism of cell detachment from temperature-modulated, hydrophilic-hydrophobic polymer surfaces. Biomaterials 1995;16:297–303.
[20] Wei H-J, Chen C-H, Lee W-Y, Chiu I, Hwang S-M, Lin W-W, Huang C-C, Yeh Y-C, Chang Y, Sung H-W. Bioengineered cardiac patch constructed from multilayered mesenchymal stem cells for myocardial repair. Biomaterials 2008;29:3547–56.
[21] Coleman and Ratcliffe. Angiogenesis: escape from hypoxia. Nat Med. 2009;15:491–3.
[22] Pugh and Ratcliffe. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9:677–84.
[23] Koike N, Fukumura D, Gralla O, Au P, Schechner JS, Jain RK. Tissue engineering: creation of long-lasting blood vessels. Nature. 2004;428:138–9.
[24] Nör JE, Peters MC, Christensen JB, Sutorik MM, Linn S, Khan MK, Addison CL, Mooney DJ, Polverini PJ. Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest. 2001;81:453–63.
[25] Schechner JS, Nath AK, Zheng L, Kluger MS, Hughes CC, Sierra-Honigmann MR, Lorber MI, Tellides G, Kashgarian M, Bothwell AL, Pober JS. In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse. Proc Natl Acad Sci U S A. 2000;97:9191–6.
[26] Au P, Tam J, Fukumura D, Jain RK. Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood. 2008;111: 4551–8.
[27] Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9:685–93.
[28] Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653–60.
[29] Hirschi KK, Rohovsky SA, D'A more PA. PDGF, TGF-beta, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol. 1998;141:805–14.
[30] Annabi B, Lee YT, Turcotte S, Naud E, Desrosiers RR, Champagne M, Eliopoulos N, Galipeau J, Béliveau R. Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells. 2003;21:337–47.
[31] Melero-Martin JM, De Obaldia ME, Kang SY, Khan ZA, Yuan L, Oettgen P, Bischoff J. Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res. 2008;103:194–202.
[32] Brooks PC, Clark RA, Cheresh DA. Requirment of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994; 264:569-571.
|
